World Health Organization Raises Warning Over Acute Scarcity of Weight-Loss Jabs
Under one in 10 people that would benefit from obesity jabs like Wegovy can access them, caution the World Health Organization as it releases its initial guidance on the medications.
Considering over a billion individuals worldwide now classified as obese, it is advocating for more widespread and fairer access to GLP-1 medication.
Based on forecasts, more than two billion are projected to be obese by 2030 unless action is taken.
"Our latest guidelines recognises that excess weight is a long-term condition that can be treated with comprehensive and ongoing care," stated WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and distribution challenges are major hurdles to universal availability to the jabs that can aid individuals in losing significant weight, explains the body.
Weight-Loss Drug Scarcity
Even under the present most favorable case, the manufacturing of such drugs might only reach about 100 million people – under 10% of eligible patients, according to the WHO.
The advice encourages nations and manufacturers to increase access, through measures such as patent sharing.
The intellectual property rights on semaglutide – the core ingredient of Novo Nordisk's Wegovy – is scheduled to end in a number of countries in 2026.
How Obesity Injections Operate
GLP-1 drugs replicate a natural hormone to slow digestion, reduce hunger and boost the sense of being full so users eat less.
People typically start to lose weight in the initial weeks of starting on the regular doses.
Research suggests patients may see weight return a year later of discontinuing the treatment, because their typical food cravings return.
Being above a healthy weight elevates your likelihood for contracting diseases, like type 2 diabetes, heart disease, brain attack, and some cancers.
Obesity concerns individuals in every country and was linked to 3.7 million fatalities worldwide in 2024, according to the health agency.